Full Press Release Details
BridgeBio Pharma Announces Positive Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I).
BBIO
BridgeBio Pharma Announces Positive Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Key Takeaway: BridgeBio Pharma Announces Positive Phase 2 Data For Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Price reaction · baseline $8.58 (2022-03-11 close) · clean, no other BBIO news in the window
day 0 close · peak
-3.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis